The abstract is read at the publisher; the summary is JClub's.
G4 and B9 are broadly neutralizing monoclonal antibodies against orthopoxviruses by targeting distinct epitopes on the MPXV M1R protein, with G4 neutralizing VACV IC50 at 37.93 pM.
- Why it matters: The 2022 mpox outbreak underscores the need for antibody-based therapeutics for OPXVs, which currently lack approved options.
- What they did: The study characterized two monoclonal antibodies, G4 and B9, for cross-reactive binding and neutralization across multiple pathogenic OPXVs, using cryo-electron microscopy to map epitope locations on M1R.
- The result: G4 neutralizes mature VACV virions with an IC50 of 37.93 pM and B9 with an IC50 of 41.13 nM, and their distinct M1R epitope targeting suggests complementary candidates for broad-spectrum prophylactic and therapeutic development.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.